The management of hematologic malignancies during the COVID-19 pandemic

Hus, Iwona; Salomon-Perzyński, Aleksander; Tomasiewicz, Krzysztof; Robak, Tadeusz

doi:10.1080/14656566.2020.1849143

Cited by 14 publications

(12 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[54][55][56] Hematological malignancies and/or blood cancer are liquid (leukemias) or are localized to sites of development and/or primary ie, bone marrow or secondary lymphoid organs, unlike most solid tumors. [57][58][59] These features make hematological malignancies highly available to interactions with immune cells and respond avidly to on-going systemic inflammatory responses (such as those observed during severe…”

Section: Sars-cov-2 Infection In Cancer Patientsmentioning

confidence: 99%

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Latif

Shukla

Estrada

et al. 2022

Translational Research

View full text Add to dashboard Cite

Section: Sars-cov-2 Infection In Cancer Patientsmentioning

confidence: 99%

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Latif

Shukla

Estrada

et al. 2022

Translational Research

View full text Add to dashboard Cite

“…Patients with hematological malignancies (lymphoma, leukemia, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid tumors (OR 1.57). As a result, many cancer organizations implemented recommendations for SARS-CoV-2 screening among patients, staff, and providers, as well as other policies aiming to minimize time in hospital, laboratory facilities, and use of telehealth resources [8][9][10][11][12][13] .…”

Section: Covid-19 and Cancermentioning

confidence: 99%

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Jiménez-Zepeda¹,

Yau²,

Stewart³

et al. 2022

RIC

View full text Add to dashboard Cite

Background:The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood. Objective: We describe a local experience of the management of MM patients and report their outcomes during the current pandemic. Methods: All consecutive symptomatic MM patients seen at our center since 03/20 were evaluated. Results: A cohort of 156 patients diagnosed from 01/19 to 12/20 was analyzed to interrogate differences in presentation patterns. A total of 553 MM patients were seen and/or treated at Tom Baker Cancer Center in the year of 2020. From those, 47.1% (n = 261) were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sixteen patients tested positive and data are presented. In addition, a decrease of 21.7% in the rate of new smoldering MM/MM diagnosis was observed in 2020 as compared to 2019. Further, an increase in deaths was also observed in 2020. Conclusions: Our study confirms an increase lethality for MM patients infected with SARS-CoV-2. A balance between safety and need for cancer control should be emphasized. (REV INVEST CLIN. [AHEAD OF PRINT]

show abstract

“…In high-risk AML, allogeneic stem cell transplantation should not be delayed. Recommendations of EBMT should be followed [42]. Tyrosine kinase inhibitors (TKIs) are the mainstay treatment in chronic myeloid leukemia (CML).…”

Section: Managing Hematologic Malignancies In Covid-19 Pandemicmentioning

confidence: 99%

“…The interaction of remdesivir with imatinib, dasatinib, and nilotinib is essential. In CML blastic phase, TKIs plus intensive chemotherapy is an urgent treatment [42].…”

Section: Managing Hematologic Malignancies In Covid-19 Pandemicmentioning

confidence: 99%

See 1 more Smart Citation

Management of Covid-19 Disease in Pediatric Oncology Patients

Cakmak¹

2021

SARS-CoV-2 Origin and COVID-19 Pandemic Across the Globe

View full text Add to dashboard Cite

Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clinical, laboratory, and radiological features. In the pediatric population, the COVID-19 disease has a mild course. Chemotherapy courses can be interrupted according to the symptoms and severity of the disease. Azithromycin, antivirals are used as a single agent or in combination. In critical patients, convalescent plasma, mesenchymal stem cells, tocilizumab, and granulocyte transfusions are administered. In recent studies, having hematological malignancy, stem cell transplantation, a mixed infection, and abnormal computerized tomography findings increase the severity of the disease and the need for an intensive care unit. Therefore, the patients and their families should be aware of a higher risk of severe forms than immunocompetent children.

show abstract

The management of hematologic malignancies during the COVID-19 pandemic

Cited by 14 publications

References 146 publications

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Management of Covid-19 Disease in Pediatric Oncology Patients

Contact Info

Product

Resources

About